Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

Suite510 Jan. 21 at 9:50 PM

$JNJ $KVUE It’s time for a 80’s throwback CNN News JULY 13, 2018 $4.69 billion verdict against Johnson & Johnson's talcum powder | CNN A US jury has ordered Johnson & Johnson to pay $4.69 billion to 22 women who alleged the powder caused their ovarian cancer. The largest verdict to date and the first to successfully argue talcum powder contains asbestos.

0 · Reply

HALOMOON Jan. 21 at 9:36 PM

YHGJ is Breaking out on fire! $RR $JNJ $COST $NOW

0 · Reply

HALOMOON Jan. 21 at 9:24 PM

$RR $IBRX $JNJ $COST here

0 · Reply

Deeznutsswapmeet Jan. 21 at 8:59 PM

$JNJ The number of idiots on here that see red pre market and think they know a thing about price action is astounding. None of you clowns have a clue about what you’re posting. Crossing your fingers and hoping you’re right is not a great strategy and shows how little you know.

0 · Reply

Deeznutsswapmeet Jan. 21 at 8:54 PM

$JNJ $MRNA Don’t change your username to try and distance yourself from those dumbass price predictions. If you don’t have a position then find another stock to spam with your garbage.

0 · Reply

Deeznutsswapmeet Jan. 21 at 8:48 PM

$JNJ $KVUE Another day, another idiotic take from this moron. He nailed again with all of his incredible market insight. Banking on lawsuits is a bad idea. Learn how corporate legal works before you decide to die on that hill. Until then, stop spamming with your made up analysis. Make sure you thank your mom and dad for the room in their house.

0 · Reply

Jamtrades Jan. 21 at 8:44 PM

All time high expected in $JNJ by Friday

0 · Reply

brief1066 Jan. 21 at 8:20 PM

$JNJ red even with the Trump pump. Doesn’t bode well.

1 · Reply

brief1066 Jan. 21 at 8:00 PM

$JNJ shorting here

1 · Reply

Quantumup Jan. 21 at 6:54 PM

Chardan🏁 $ALMS Buy/$37 $BMY $TAK ABBV $JNJ - $PTGX NVS LLY Here's what Chardan said in its initiation report: https://x.com/Quantumup1/status/2014048081944182966?s=20

0 · Reply

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Jan 21, 2026, 12:15 PM EST - 5 hours ago

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

Jan 21, 2026, 10:00 AM EST - 7 hours ago

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

OKLO ULTA

Jan 21, 2026, 7:26 AM EST - 10 hours ago

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Jan 21, 2026, 6:23 AM EST - 11 hours ago

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Jan 21, 2026, 6:20 AM EST - 11 hours ago

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Jan 21, 2026, 6:20 AM EST - 11 hours ago

Johnson & Johnson reports Q4 and Full-Year 2025 results

Jan 21, 2026, 1:07 AM EST - 16 hours ago

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Jan 20, 2026, 8:37 AM EST - 1 day ago

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

Jan 19, 2026, 8:00 AM EST - 2 days ago

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Jan 19, 2026, 5:08 AM EST - 2 days ago

Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)

$TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide$

Jan 14, 2026, 4:30 PM EST - 7 days ago

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Jan 13, 2026, 8:00 AM EST - 8 days ago

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Jan 13, 2026, 2:40 AM EST - 8 days ago

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

DHR GOOG LIN MSFT ORCL

Jan 12, 2026, 6:32 PM EST - 8 days ago

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Jan 12, 2026, 2:06 PM EST - 9 days ago

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 7:40 AM EST - 10 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD KO MRK NKE PG

Jan 10, 2026, 10:00 AM EST - 11 days ago

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Jan 10, 2026, 9:52 AM EST - 11 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON KO MRK

Jan 9, 2026, 9:59 AM EST - 12 days ago

Cramer's Mad Dash: Johnson & Johnson

Jan 9, 2026, 5:10 AM EST - 12 days ago

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Jan 8, 2026, 9:33 PM EST - 12 days ago

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Jan 8, 2026, 8:43 PM EST - 12 days ago

Johnson & Johnson reaches deal with US government to lower drug prices

Jan 8, 2026, 8:24 PM EST - 12 days ago

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Jan 7, 2026, 8:00 AM EST - 14 days ago

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Jan 6, 2026, 8:03 AM EST - 15 days ago

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

$Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma$

Jan 6, 2026, 6:52 AM EST - 15 days ago

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Jan 2, 2026, 5:06 PM EST - 19 days ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

AMGN CVX HD KO MRK NKE PG

Jan 2, 2026, 4:17 PM EST - 19 days ago

Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers

CAT NVDA GS IBM

Jan 2, 2026, 8:00 AM EST - 19 days ago

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Dec 31, 2025, 8:47 AM EST - 21 days ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

Dec 30, 2025, 1:31 PM EST - 22 days ago

The Big 3: JNJ, SNDK, TWLO

TWLO SNDK

Dec 30, 2025, 9:55 AM EST - 22 days ago

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

Dec 30, 2025, 5:05 AM EST - 22 days ago

More Upside For JNJ Stock In 2026?

Dec 29, 2025, 1:56 PM EST - 23 days ago

Dogs of the Dow Had a Strong Year as Dividends Paid Off

HD IBM NKE UNH

Dec 29, 2025, 8:00 AM EST - 23 days ago

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Dec 28, 2025, 6:44 AM EST - 24 days ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BDX

Dec 26, 2025, 8:13 AM EST - 26 days ago

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Dec 23, 2025, 11:41 AM EST - 4 weeks ago

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

Dec 23, 2025, 12:34 AM EST - 4 weeks ago

J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award

Dec 22, 2025, 11:15 PM EST - 4 weeks ago

Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

Dec 20, 2025, 3:55 AM EST - 4 weeks ago

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

Dec 19, 2025, 5:54 PM EST - 4 weeks ago

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Dec 18, 2025, 8:00 AM EST - 4 weeks ago

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Dec 18, 2025, 2:09 AM EST - 4 weeks ago

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Dec 17, 2025, 6:49 PM EST - 4 weeks ago

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

Dec 15, 2025, 6:22 PM EST - 5 weeks ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER

Dec 15, 2025, 4:27 PM EST - 5 weeks ago

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Dec 15, 2025, 10:39 AM EST - 5 weeks ago

US FDA grants priority voucher to J&J's blood cancer treatment

Dec 14, 2025, 9:00 AM EST - 5 weeks ago

California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson

Suite510 Jan. 21 at 9:50 PM

0 · Reply

HALOMOON Jan. 21 at 9:36 PM

YHGJ is Breaking out on fire! $RR $JNJ $COST $NOW

0 · Reply

HALOMOON Jan. 21 at 9:24 PM

$RR $IBRX $JNJ $COST here

0 · Reply

Deeznutsswapmeet Jan. 21 at 8:59 PM

0 · Reply

Deeznutsswapmeet Jan. 21 at 8:54 PM

$JNJ $MRNA Don’t change your username to try and distance yourself from those dumbass price predictions. If you don’t have a position then find another stock to spam with your garbage.

0 · Reply

Deeznutsswapmeet Jan. 21 at 8:48 PM

0 · Reply

Jamtrades Jan. 21 at 8:44 PM

All time high expected in $JNJ by Friday

0 · Reply

brief1066 Jan. 21 at 8:20 PM

$JNJ red even with the Trump pump. Doesn’t bode well.

1 · Reply

brief1066 Jan. 21 at 8:00 PM

$JNJ shorting here

1 · Reply

Quantumup Jan. 21 at 6:54 PM

Chardan🏁 $ALMS Buy/$37 $BMY $TAK ABBV $JNJ - $PTGX NVS LLY Here's what Chardan said in its initiation report: https://x.com/Quantumup1/status/2014048081944182966?s=20

0 · Reply

maikl_211 Jan. 21 at 6:31 PM

$XOM $JNJ $ASML $MA $NVDA Polestar. This opportunity is here to stay. This company will have a very significant impact in the future, and you'll remember what I'm saying. It's the only company, along with Tesla, that specializes in electric vehicles. While Tesla produces low-quality, cheap plastic products, patience and more investment are key. Polestar manufactures in China, Europe, Korea, and the United States, and is expanding globally, already holding a market share.

1 · Reply

Suite510 Jan. 21 at 6:07 PM

$JNJ $KVUE $SPX Lost Special Master Ruling Lost Dissmal of Top Talc Lawyer lol 😂 More fun to come

0 · Reply

EquityResearchsheet Jan. 21 at 5:50 PM

$JNJ 4Q25 - Solid Q. Strong outlook. Bull case $260 Bear case $180 https://open.substack.com/pub/richiericheps/p/jnj-4q25-solid-q-strong-outlook-bull?r=b9ngl&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

0 · Reply

StockBraker Jan. 21 at 5:21 PM

$JNJ If we can stay (somewhat) in this 6 month channel for another 6 months I think we will all be very happy.

1 · Reply

BritCharts Jan. 21 at 4:47 PM

$JNJ defensive mega-cap, slow tape, rotation play if risk-off returns

0 · Reply

MoneyGroupLLC Jan. 21 at 4:38 PM

Enter: $JNJ Calls Strike Price: $220 Expiry Date: FEB 13 2026 Buy in Price: $4.80 - $5.04 Sell Price: $7.54 Profit : +57% (Turn every $1 into $1.57) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

ZacksResearch Jan. 21 at 4:27 PM

$JNJ beats Q4 estimates — yet the stock is down. What’s the market missing? ⚠️ J&J topped Q4 earnings and sales estimates, with strong oncology drug growth led by Darzalex helping offset biosimilar pressure on Stelara. Solid results, but investors are clearly weighing the mix. See the full breakdown and what’s driving the reaction 👉 https://www.zacks.com/stock/news/2820495/jj-stock-down-despite-q4-earnings-beat-oncology-drugs-drive-sales?cid=sm-stocktwits-2-2820495-teaser-29858&ADID=SYND_STOCKTWITS_TWEET_2_2820495_TEASER_29858

0 · Reply

ZacksResearch Jan. 21 at 3:27 PM

$JNJ beats Q4 earnings & sales estimate, but shares dip 3%! 🤔 🔹 Earnings of $2.46/share vs. $2.43 estimate 🔹 Sales up 9.1% YoY at $24.56B, beating $24.12B estimate 🔹 Innovative Medicines unit shines, but Stelara's sales slump weighs on market reaction Find out what's driving the market's reaction here 👉 https://www.zacks.com/stock/news/2820495/jj-stock-down-despite-q4-earnings-beat-oncology-drugs-drive-sales?cid=sm-stocktwits-2-2820495-body-29857&ADID=SYND_STOCKTWITS_TWEET_2_2820495_BODY_29857

0 · Reply

TraderlyDiscord Jan. 21 at 3:18 PM

> __**MY TOP WATCHES FOR TODAY**__ > __**Other**__ > $SMCI > $UAL > $BABA > $JNJ > $MSTR

0 · Reply

OceanBush85 Jan. 21 at 3:10 PM

$JNJ Unilever’s rep: blue-chip, boringly huge, freight everywhere. RIME’s rep: tiny, high-beta, AI logistics story with SemiCab under the hood. So when the PR says a Unilever subsidiary pumped the deal 10x+ over pilot value and dropped $1,600,000 into SemiCab’s corridor… that’s the exact kind of under-the-radar partnership that later looks obvious AF in hindsight 😂📈

0 · Reply

cmgventure Jan. 21 at 3:07 PM

$JNJ | Johnson & Johnson beat revenue estimates in Q4 and provided strong guidance. The stock is -1.0% this morning. 🔹 EPS: $2.46 vs. $2.46 est. 🟠 🔹 Revenue: $24.56B vs. $24.15B est. ✅ Key takeaways: 🔸 Innovative med revenue: +10% YoY 🔸 MedTech revenue: +8% YoY 🔸 US customer sales: +8% YoY 🔸 FY revenue outlook: ~$100.5B (+7% YoY) 🔸 FY EPS outlook: ~$11.53 (+7% YoY)

0 · Reply

InfinityVenom Jan. 21 at 3:06 PM

$JNJ Up from here

0 · Reply

Market Cap	526.82B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	21.15
Forward PE	19.08
Profit Margin	15.84%
Debt to Equity Ratio	0.50

Volume	14,737,849
Avg Vol	8,851,592
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	88%
Beta	0.34
Analysts	Strong Sell
Price Target	$213.83